















































Diabetes mellitus is the most prevalent metabolic 
disorder, and its metabolic hallmark, glucose 
intolerance, affects approximately 344 million people 
worldwide [1]. There are two prominent subtypes of 
diabetes mellitus, named type 1 and type 2, 
















































secretion of insulin from pancreatic beta-cells. While 
type 1 diabetes is considered an autoimmune disease 
leading to slowly progressive and ultimately complete 
loss of pancreatic beta-cells, type 2 diabetes is caused 
by a combination of peripheral insulin resistance and 
beta-cell dysfunction. Recent evidence however 
suggests that type 2 diabetes is additionally 
characterized by impaired beta-cell regeneration and 
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terminal sequences, so-called telomeres, which are 
essential for chromosome stability. Telomeric DNA is 
synthesized, elongated and hence maintained by 
copying an RNA template sequence within the RNA 
moiety of an enzyme called telomerase. The respective 
subunit of telomerase is encoded by the telomerase RNA 
component  (Terc) gene. Significant evidence suggests 
that telomeres and telomerase activity have a crucial 
role in regulating cell survival and regeneration [6-8].   
  
Given the role of telomerase in maintenance and 
replication of differentiated cells on the one hand, and 
the importance of beta-cell loss for the pathogenesis of 
type 1 as well as type 2 diabetes on the other hand, it 
appears tempting to hypothesize that telomerase could 
act as key regulator of beta-cell viability and 
regeneration. We therefore here have analyzed 
previously generated mice [9,10] that are deficient for 
the  telomerase RNA component (Terc) gene in this 
regard. We find that these animals develop glucose 
intolerance and impaired insulin secretion due to 




Body composition and energy expenditure in Terc-/- 
G4 mice 
 
As previously reported [9,10], Terc -/- G4 mice are 
smaller and have reduced body mass (Figure 1A). 
However, we here show that this reduction affects both 
lean mass (Figure 1B) and body fat (Figure 1C) to the 
same extent. We moreover demonstrate that both 
dietary energy uptake (Figure 1D) and energy excretion 
via faeces (Figure 1E) is reduced. However when these 
latter findings are normalized to body mass, no 
significant differences can be found for neither energy 
uptake nor energy excretion (data not shown). 
Furthermore, no glucosuria was detected in none of the 
genotypes (data not shown), precluding differential loss 
of energy via urine. Accordingly determination of 
energy expenditure as quantified by indirect calorimetry 
did not show any differences regarding energy turnover 
at neither day- nor night-time (Figure 1F). 
 
Taken together these findings indicate that Terc -/- G4 
mice are smaller but have an unaltered relative body 
composition and energy metabolism. 
 
Metabolic plasma markers in Terc -/- G4 mice 
 
We quantified concentrations of glucose (fasted and fed 
states), insulin (fasted and fed states), triglycerides, non-
esterified fatty acids, total cholesterol and alanine 
aminotransferase (all fasted) in plasma samples of the 
animals, and found no differences between Terc -/- G4 



















































Glucose metabolism in Terc -/- G4 mice 
 
We next performed intra-peritoneal glucose tolerance 
tests (ipGTT) on Terc -/- G4 and on the control 
Figure 1. Impaired telomerase activity – Effects on body








Terc‐/‐  G4).  (F)  Total  energy  expenditure  normalized  to  body
mass of mice as in Panel A (n=10 controls, n=10 Terc‐/‐ G4).  
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Terc -/- G4 mice (Figure 2A). We then aimed to 
elucidate whether impaired insulin secretion or rather 
insulin resistance may be responsible for this 
phenotype. We therefore first quantified plasma insulin 
levels during conditions of ipGTT, and observed 
impaired insulin secretion in response to injected 
glucose in Terc -/- G4 mice (Figure 2B). By contrast, 
performing intra-peritoneal insulin tolerance tests 















































nificant differences in glucose disposal in response to 
insulin (Figure 2C). Since telomerase has been reported 
to affect mitochondrial function [11,12], we lastly 
quantified glucose oxidation rates by injecting 
uniformly 
13C-labeled glucose to quantify the exhalation 
of 
13CO2, which was found to be identical in all 
genotypes (Figure 2D), precluding systemic 
mitochondrial dysfunction in Terc -/- G4 mice, at least 



























































www.impactaging.com                    652                                    AGING, October 2010, Vol.2 No.10Since the phenotype appeared to be restricted to impaired 
insulin secretion, we next quantified telomere length 
specifically in pancreatic islets. Using quantitative 
fluorescence in situ hybridization (qFISH) (Figure 2 E, F) 




















































length in islets of Terc -/- G4 animals (Figure 2G). 
 
Taken together, telomerase deficiency causes shortened 
telomere length in pancreatic islets, and impaired glucose 
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Reduced insulin secretion is typically caused by 
reduced mass of the islets of Langerhans, which mainly 
contain beta cells. To decide whether this possibility 
may apply in regards to the phenotype observed (Figure 
2 A, B), we first determined beta-cell mass in repeated 
sections from pancreata of all four genotypes by 
quantitative microscopy. We firstly observed smaller 
islets in mice deficient for Terc (Figure 3B) as 
compared to control animals (Figure 3A).  By 
morphometrically quantifying insulin-positive areas 
within pancreatic sections of all genotypes, we 
consistently found a reduction of insulin-positive areas 
per total pancreatic section (Figure 3C). Since Terc -/- 
G4 are smaller than control genotypes (Figure 1A), we 
normalized pancreatic and insulin-positive areas to body 
mass to exclude the possibility that reduced insulin-
positive area size simply was an indicator of reduced 
body mass. After normalizing the areas for body mass, 
we still observe a significant reduction of insulin-
positive areas (Figure 3D). 
 
We moreover find the number of islets to be reduced 
in Terc -/- G4 animals (Figure 3E) which however 
did not apply after normalization for body mass 
(Figure 3F, P=n.s.). Most importantly, we find the 
insulin-positive area per individual islet of 
Langerhans to be reduced in absolute terms (Figure 
3G) as well as after normalization for body mass 
(Figure 3H), altogether suggesting that telomerase 
deficiency causes a reduction of beta cell mass by 
reducing the size of individual islets whereas islet 
number is not affected.  
 
Impaired beta-cell regeneration in Terc -/- G4 mice 
 
  We next injected bromo-desoxyuridine (BrdU) into 
mice prior to sacrifice which enables us to determine 
the number of DNA-replicating, i.e. dividing beta cells, 
after counterstaining with an anti-BrdU antibody. We 
found a reduction of BrdU-positive beta-cells per islet 
(Figure 4A) as well as after normalization for body 
mass (Figure 4B). Lastly, the number of BrdU-positive 
beta-cells per standardized insulin-positive area was 
also found to be reduced (Figure 4C) as well as after 
normalization for body mass (Figure 4D).  
 
Taken together, these findings indicate that telomerase 
deficiency as found in Terc -/- G4 animals causes 
reduced beta-cell mass due to impaired regenerative 
capacity of pancreatic islets of Langerhans, culminating 
in impaired glucose tolerance due to reduced insulin 









































We here describe a direct causal link between impaired 
telomerase activity and impaired insulin secretion as 
well as glucose intolerance in Terc-/- G4 mice. These 
findings are supported by the fact that shortened 
telomeres, as found in states of reduced telomerase 
activity, are associated with type 2 [13-20] as well as 
possibly type 1 diabetes mellitus [21,22] in humans. As 
stated in the introductory section, both disorders exhibit 
patterns of impaired insulin secretion. 
 
According to our findings, glucose intolerance in Terc-
/- G4 animals is caused by reduced insulin secretion 
Figure  4.  Impaired  telomerase  activity  reduces  islet
number and size by impairing the replicative potential of
pancreatic  beta‐cells.  (A,  B)  shows  the  number  of  BrdU‐
positive cells per insulin‐positive area (A) and after additional
normalization  to  body  mass  (B).  (C,  D)  depict  the  number  of
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unaffected. This latter observation is in conflict with pre- 
vious reports that shortened telomeres in humans are 
associated with insulin resistance [14,23-25], a state in 
which insulin sensitivity is reduced. However and since 
insulin secretion and insulin sensitivity appear to 
influence each other primary disturbances in insulin 
secretion may secondarily affect insulin resistance. 
 
Progressive beta-cell failure and senescence are 
hallmarks of type 2 diabetes [2-5]. More specifically, 
telomere shortening has been shown to determine the 
risk of beta-cell growth arrest and cellular senescence in 
adult human islet cells [26]. The Tert  gene is 
moderately expressed in islets from different mouse 
models, including C57BL/6 (the strain used in the 
present study), and expression levels interestingly 
appear to decrease with age [27]. Moreover, significant 
telomerase activity can be detected in islet extracts from 
C57BL/6 mice [27]. Interestingly, telomerase appears to 
counteract the senescence-promoting effects of 
hyperglycemia, at least in vitro [28]. Moreover, several 
of the known downstream targets of telomerase have 
been identified to affect islet cell growth and 
regeneration [29,30], whereas a link to telomerase 
deficiency had not been established. Further studies will 
have to elucidate whether our current findings and these 
putative downstream effectors converge in deterioration 
of islet mass and hence development of diabetes 
mellitus. 
 
Taken together, our findings indicate that reduced 
telomerase activity may be considered a cause of 
impaired glucose tolerance and hence diabetes mellitus. 
In full accordance with the role of this protein in 
multiple other cell types, telomerase is required to 
maintain the replicative potential of pancreatic beta-
cells. Consistently, lack of telomerase activity causes 
beta-cell loss and subsequent deterioration of glucose 
metabolism, reflecting the increasing incidence of 
diabetes mellitus with increasing age. 
 
MATERIALS AND METHODS 
 
Generation and maintenance of mice. Four genotypes of 
the previously described Terc -/- animals were studied: 
While Terc -/- G4 mice have been intercrossed for three 
generations with Terc-deficient littermates, Terc-/- G1 
have parents that were both heterozygous for the Terc 
disruption. The latter served as controls, in addition to 
wild-type and heterozygous Terc +/- animals, since 
significant telomere shortening is absent in such Terc -/- 
G1 animals [9,10]. Tail-biopsy genomic PCR for 
detection of the Terc-/- allele was performed as 
previously described [10]. Animals were housed in air-
conditioned rooms (temperature, 20 ± 2 °C; relative 
moisture, 50 – 60 %) under a 12-hour-light/dark 
schedule (lights on at 06:00 hrs) and had free access to 
standard chow (Ssniff R/M-H, Ssniff Spezialdiäten 
GmbH, Soest, Germany) and water. Mice were studied 
at an age of 19 - 24 weeks, and were kept in accordance 
with the National Institutes of Health guidelines for the 
care and use of laboratory animals, and all experiments 
were approved the corresponding institutional review 
boards. 
 
Body composition analysis.  Body mass and body 
composition (including fat content) were measured by 
use of quantitative nuclear magnetic resonance 
technique (Echo MRI-100 Body Composition Analyzer, 
Echo Medical Systems, Houston, TX) as previously 
described [31]. 
 
Food consumption quantification.  Food intake was 
recorded weekly and faeces were collected 3 times per 
week. After freeze-drying energy content of diet and 
faeces samples was determined by bomb calorimetry 
(IKA C5003, IKA Werke GmbH, Staufen, Germany) as 
previously described [31]. 
 
Respiratory quotient and energy expenditure.  Total 
energy expenditure and respiratory quotient were 
determined by indirect calorimetry of mice housed 
individually in metabolic cages, receiving food and 
water ad libitum as described using a TSE LabMaster 
Calorimetry Module (TSE, Bad Homburg, Germany) 
[31].  
 
Insulin and glucose tolerance tests.  Glucose tolerance 
tests were performed as described [31] by 
intraperitoneal (ip) glucose injection of 1 g per kg body 
mass of D-(+)-glucose (Merck, Darmstadt, Germany) 
after mice were fasted 16 hrs overnight. Insulin 
tolerance tests were performed by intraperitoneal (ip) 
injection of 1 U insulin per kg body mass as described 
[32]. 
 
Plasma and serum analyses.  All blood samples were 
obtained, prepared, stored and measured exactly as 
previously described [31].  
 
13CO2 breath tests for glucose oxidation experiments. 
13CO2 breath tests were applied as non-invasive 
methods to study the oxidation of injected or ingested 
13C-labeled glucose exactly as previously described 
[31].  
 
Quantification of pancreas and islet sizes.  All 
procedures, including immuno-histochemistry for 
insulin, BrdU-injection and detection were performed as 
described [32] while digitizing and quantification for 
beta-cell-mass was performed with a MiraxMidi slide 
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software (both from Carl Zeiss MicroImaging, Jena, 
Germany).  
 
Telomere length. in pancreatic islets was determined on 
sections as above using quantitative fluorescence in situ 
hybridization (qFISH) according to previously reported 
methods [33]. The relative telomere length was 
determined by the fluorescence intensity using the TFL 
software package [34]. 
. 
Data analysis.  Data are expressed as mean ± SEM. 
Number of animals analyzed is given in the respective 
figure legends. Equal distributions were tested by 
Kolmogorov-Smirnov test before applying T-tests. 
Unpaired Student´s T-tests were used to compare Terc-
/-  G4, Terc -/-  G1, Terc +/- and wild-type animals by 
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Effects of impaired telomerase activity on metabolic serum markers. (A, B) Fasting plasma glucose (A) and insulin (B) levels
of mice that were food deprived for 16 hrs (C, D) Postprandial plasma glucose (C) and insulin (D) levels of mice that had ad libitum
access to diet over night. (E to H) Fasting serum triglyceride (E), non‐esterified fatty acid (F), total cholesterol (G) and alanine
aminotransferase (ALAT) (H) levels. Black bars reflect control genotypes (n=42) and grey bars indicate Terc‐/‐ G4 animals (n=19). 